Statera Biopharma Stock Fundamentals
| STAB Stock | USD 0.0001 0.0001 50.00% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Statera Biopharma's long-term financial health and intrinsic value.
Statera |
Statera Biopharma Company Return On Equity Analysis
Statera Biopharma's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Statera Biopharma Return On Equity | -2.87 |
Most of Statera Biopharma's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Statera Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Statera Biopharma has a Return On Equity of -2.8694. This is 88.03% lower than that of the Healthcare sector and 92.13% lower than that of the Biotechnology industry. The return on equity for all United States stocks is notably higher than that of the company.
Statera Biopharma Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Statera Biopharma's current stock value. Our valuation model uses many indicators to compare Statera Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Statera Biopharma competition to find correlations between indicators driving Statera Biopharma's intrinsic value. More Info.Statera Biopharma is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Statera Biopharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Statera Biopharma's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Did you try this?
Run Options Analysis Now
Options AnalysisAnalyze and evaluate options and option chains as a potential hedge for your portfolios |
| All Next | Launch Module |
Statera Fundamentals
| Return On Equity | -2.87 | |||
| Return On Asset | -0.24 | |||
| Operating Margin | (5.73) % | |||
| Current Valuation | 12.92 M | |||
| Shares Outstanding | 54.66 M | |||
| Shares Owned By Insiders | 15.93 % | |||
| Shares Owned By Institutions | 5.41 % | |||
| Number Of Shares Shorted | 1.25 M | |||
| Price To Book | 0.16 X | |||
| Price To Sales | 1.61 X | |||
| Revenue | 1.49 M | |||
| Gross Profit | 998.72 K | |||
| EBITDA | (97.27 M) | |||
| Net Income | (101.88 M) | |||
| Cash And Equivalents | 506.1 K | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 10.62 M | |||
| Debt To Equity | 0.23 % | |||
| Current Ratio | 0.05 X | |||
| Book Value Per Share | (0.20) X | |||
| Cash Flow From Operations | (28.19 M) | |||
| Short Ratio | 0.39 X | |||
| Earnings Per Share | (0.76) X | |||
| Number Of Employees | 46 | |||
| Market Capitalization | 1.97 M | |||
| Total Asset | 21.17 M | |||
| Z Score | -13.2 | |||
| Net Asset | 21.17 M |
About Statera Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Statera Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Statera Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Statera Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropeniaanemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the bodys immune system and restore homeostasis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. Statera Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 46 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Statera Pink Sheet
Statera Biopharma financial ratios help investors to determine whether Statera Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Statera with respect to the benefits of owning Statera Biopharma security.